Study | Exclusion reasons | Remarks | Reference(s) | ||
---|---|---|---|---|---|
HYDRA, 2020 | randomized controlled trial | Initially found in Axfors et al. meta-analysis results published by Hernadez et al | |||
BCN PEP-CoV-2-Study 2 (Mitja Lancet-preprint), 2020 | randomized controlled trial | ||||
Mohana, 2020 | retrospective cohort (claims database) | no control group |
Mohana A Int J Infect Dis 2020 Oct 16;S1201-9712(20)32235-9. 10.1016/j.ijid.2020.10.031 |
||
Kanran M, 2020 | randomized controlled trial | other | randomization process unclear : Thepatients who did not give consent for treatment with HCQ or had a known allergy to HCQ orchloroquine or had another known contraindication to treatment with the study drug, includingretinopathy, G6PD deficiency and QT prolongation served as controls | ||
Alberici, 2020 | retrospective cohort | other | HCQ efficacy or safety evaluation wasn't a prespecified endpoint |
Alberici F Kidney Int 2020 Jul;98(1):20-26. 10.1016/j.kint.2020.04.030 |